Edition:
United States

AB Science SA (ABS.PA)

ABS.PA on Paris Stock Exchange

10.04EUR
18 Aug 2017
Change (% chg)

€-0.20 (-1.95%)
Prev Close
€10.24
Open
€10.23
Day's High
€10.23
Day's Low
€10.02
Volume
33,932
Avg. Vol
195,987
52-wk High
€18.07
52-wk Low
€9.09

ABS.PA

Chart for ABS.PA

About

AB Science SA, also known as AB Science, is a France-based pharmaceutical company specialized in the research, discovery, development and marketing of protein kinase inhibitors (PKIs). It is engaged in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical factor in the field of cancer,... (more)

Overall

Beta: 1.85
Market Cap(Mil.): €409.53
Shares Outstanding(Mil.): 40.79
Dividend: --
Yield (%): --

Financials

  ABS.PA Industry Sector
P/E (TTM): -- 31.45 32.56
EPS (TTM): -0.78 -- --
ROI: -169.73 15.33 14.89
ROE: -- 16.35 16.13

BRIEF-AB Science announces issuance of a new european patent

* REG-AB SCIENCE ANNOUNCES ISSUANCE OF A NEW EUROPEAN PATENT FOR PROTECTING THE USE OF MASITINIB IN PANCREATIC CANCER PATIENTS

Jul 12 2017

BRIEF-AB Science presents supportive data from its phase 3 study in severe systemic mastocytosis

* PRESENTS SUPPORTIVE DATA FROM ITS PHASE 3 STUDY IN SEVERE SYSTEMIC MASTOCYTOSIS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jun 22 2017

BRIEF-EU Medicines Agency recommends against approval of AB Science mastocytosis drug Masitinib

* EU Medicines Agency recommends approval of Valeant Pharmaceuticals Inc psoriasis drug Brodalumab

May 19 2017

BRIEF-AB Science presents Phase 3 data for Masitinib in amyotrophic lateral sclerosis (ALS)

* PRESENTS PHASE 3 DATA FOR MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS (ALS)

May 18 2017

BRIEF-Ab Science: CHMP adoptes negative opinion for masitinib in indolent systemic mastocytosis

* REG-AB SCIENCE ANNOUNCES THAT CHMP HAS ADOPTED A NEGATIVE OPINION FOR MASITINIB IN INDOLENT SYSTEMIC MASTOCYTOSIS, PRIMARILY DUE TO GCP INSPECTION FINDINGS

May 17 2017

BRIEF-Trading resumption on shares of AB Science

* Announced today that trading on ordinary shares issued by AB Science will resume on Euronext Paris as of May 16, 2017 at 0900 CET Further company coverage: (Gdynia Newsroom)

May 15 2017

BRIEF-AB Science - ANSM requested temporary suspension of masitinib studies

* Notification from ANSM requesting temporary suspension of ongoing masitinib studies until compliance is confirmed by an external audit

May 11 2017

BRIEF-AB Science FY net loss widens to 27.7 million euros

* Reported on Monday FY net revenues of 1.5 million euros ($1.64 million) versus 2.3 million euros a year ago

May 02 2017

BRIEF-AB Science issues 1.2 mln new ordinary shares - Euronext

* AB Science SA issues 1,241,831 new ordinary shares, which will be listed on Euronext Paris market as of April 4, 2017 Further company coverage: (Gdynia Newsroom)

Mar 31 2017

BRIEF-Ab Science announces that masitinib passed its non-futility test at 2 years

* Announces that masitinib study in primary and secondary progressive forms of multiple sclerosis has passed its non-futility test at 2 years

Mar 29 2017

Earnings vs. Estimates